Andrew Walsh

Andrew Walsh currently serves as Vice President of Finance at XyloCor Therapeutics, Inc. since August 2025. Prior to this role, Andrew held the position of VP Finance and Principal Financial Officer at Annovis Bio, Inc. from December 2023 to August 2025, and served as Senior Director of Finance and Treasury at Ocugen from April 2022 to December 2023, where responsibilities included managing SEC reporting and corporate finance operations for a clinical stage biopharmaceutical company. Before Ocugen, Andrew worked as Director of Tax and Treasury at Potters Industries and held key roles at PQ Corporation and inVentiv Health Clinical, focusing on tax and financial management. Andrew began a career in finance at KPMG as a Senior International Tax Associate and holds a degree in Business with a concentration in Accounting from Drexel University.